Physician profile
Augusto Fojas
NPI 1205891710
$4,267.08
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,209 · 2020: $1,042 · 2021: $970 · 2022: $697 · 2023: $296 · 2024: $52.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $905.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $722.66 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $478.72 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $319.09 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $233.92 | 2019-2021 | |
| Daiichi Sankyo INC. | $220.69 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $167.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.39 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $148.69 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $143.84 | 2019-2021 | |
| Amarin Pharma, INC. | $127.43 | 2020-2021 | |
| Medtronic Vascular, INC. | $126.20 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $104.50 | 2021 | |
| Jazz Pharmaceuticals INC. | $91.38 | 2021 | |
| Sunovion Pharmaceuticals INC. | $64.02 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $58.06 | 2019-2021 | |
| Celgene Corporation | $53.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.90 | 2019-2021 | |
| Corcept Therapeutics | $35.41 | 2021 | |
| Sanofi-Aventis U.S. LLC | $30.10 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.68 | 2019-2020 | |
| Pfizer INC. | $13.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augusto Fojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.